Menopause, the permanent cessation of menstruation, occurs at the mean age of 49.7 years in Korea.
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transdermal estrogen over oral administration on relief of vasomotor symptoms and protection of bone loss in postmenopausal women. 11, 12 However, in Korea, there have been only a few reports on effects of transdermal estrogen in postmenopausal women, and most of them were regarding the effects on symptom relief or lipid metabolism, and skeletal protective effect was rarely addressed. 13~18 The aim of the present study was to compare the effects of estrogen on bone according to route of administration in postmenopausal Korean women.
Materials and Methods
This retrospective study included 149 healthy postmenopausal women: 100 women who received HT at Samsung
Medical Center Menopause Clinic, and 49 women who had annual routine checkups at Samsung Medical Center for Health Promotion. Women without menstruation for at least 12 months or those with serum level of follicle stimulating hormone over 40 mIU/mL were defined as postmenopausal.
Only women with baseline and annual follow up results of bone mineral density (BMD) for two years were eligible for this study. Exclusion criteria were prior exposure to HT within 6 months from the baseline and a history of diseases or medications that can affect BMD. In addition, women who changed the route of estrogen administration during the follow up were also excluded.
Women in HT group were treated with either oral (n = 46) or transdermal estrogen (n = 54). Oral estrogens were conjugated equine estrogen (CEE) 0.625 mg or equivalent, and transdermal estrogens were a patch (estradiol 1. Results Table 1 presents clinical characteristics at the baseline.
There were no differences in age, age at menarche, age at menopause, parity, body mass index (BMI), and type of menopause among the oral or transdermal estrogen, and the control groups. Standardized baseline BMD at both the lumbar spine and the total hip also did not differ by group (Table 1) .
BMD increased after HT (oral or transdermal), while it decreased in control group during the follow up period, showing significant differences at both the lumbar spine and the total hip, respectively (P < 0.05 and P < 0.01; Fig. 1 ).
In women who received estrogen alone (n = 31), the changes of BMD were not significantly different between the oral (n = 16) and transdermal (n = 15) route (Fig. 2) .
Changes in BMD were compared according to the addition of progestogen. Figure 3 shows the changes in BMD between estrogen alone and estrogen combined with progestogen groups within oral HT group. BMDs increased in both groups without significant differences. In addition, within transdermal estrogen group, the pattern of BMD changes was also not different between estrogen alone and estrogen combined with progestogen groups (Fig. 4) . Based on these findings, data on estrogen alone and estrogen combined with progestogen were pooled in the subsequent analysis, and comparisons were made only according to the route of estrogen administration. In addition, within transdermal group, the changes of BMD were not different according to the type of transdermal estrogen -gel or patch (data not shown).
Discussion
The present study compared changes in BMD according to the route of estrogen in postmenopausal Korean women, and demonstrated a positive effect of transdermal estrogen therapy on BMD, which was comparable to that of oral estrogen therapy.
Changes of BMD did not differ by addition of progestogen in both oral and transdermal estrogen groups, which is consistent with the results of a previous study showing no significant differences in BMD according to progestogen addition. 11 Checa and colleagues 22 also reported comparable odds ratios for bone loss in both the estrogen and estrogenprogestogen therapy. However, there are still conflicting results about the effect of progestogen addition on bone mass. A previous randomized trial reported that addition of medroxyprogesterone acetate (MPA) to CEE showed greater increase in spine BMD than CEE-alone. 23 In addition, another randomized trial also showed additional gain in 32 and BMDs in postmenopausal Caucasian women were higher than those in Asian women at the total hip and spine, but lower than those in African-American women at the hip. 29, 33 Consequently, the prevalence of osteoporosis (37.0%) in Korea is higher than in Caucasian women. 34, 35 However, fracture rates were lower in Asian women than Caucasian women, and this discrepancy might also be explained by ethnic differences in bone microarchitecture or thickness and density of cortex. 36, 37 In spite of ethnic differences in bone metabolism, there To the best of our knowledge, this is the first report that compared beneficial effect of transdermal estrogen on bone with oral route in postmenopausal Korean women.
Nevertheless, the present study has some limitations mostly stemming from small sample size and retrospective design. In addition, fracture risk was not assessed.
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Use of two different DXA systems might affect precise comparisons, although BMD measurement was converted into standardized BMD for comparison.
19~21
In conclusion, transdermal estrogen therapy increases BMD, to a similar degree with oral estrogen in postmenopausal Korean women.
